Biotechnology company Moderna (MRNA.US) has received approval from the U.S. Food and Drug Administration (FDA) for a new COVID-19 vaccine, with shares rising 4% in pre-market trading on Monday.
The new vaccine, named mNexspike, is not a substitute for existing vaccine doses; it is a lower dose, one-fifth of the current COVID-19 vaccine dose, and will be achieved through improved immune targets

MRNA

Biotechnology company Moderna has received approval from the U.S. Food and Drug Administration (FDA) for a new COVID-19 vaccine, with shares rising 4% in pre-market trading on Monday. The new vaccine, named mNexspike, is not a substitute for existing vaccine doses; it is a lower dose, one-fifth of the current COVID-19 vaccine dose, and will be achieved through improved immune targets

Moderna's COVID-19 vaccine received FDA approval, pre-market stock price rose by 4%